ライフサイエンスコーパス: sibutramine

1 rter, and GNbeta3 genes and weight loss with sibutramine.

2 reported by participants who received BT and sibutramine.

3 m2) for a 6-month period of weight loss with sibutramine (10 mg/day) and an individualised 600 kcal/d

4 rmacogenetic study of behavioral therapy and sibutramine (10 or 15 mg daily) or placebo for 12 weeks

5 Sibutramine, 10 and 15 mg, caused weight loss (P = .009)

6 All participants received sibutramine, 10 mg/d; a lifestyle manual; and access to

7 andomly assigned to 24 weeks of double-blind sibutramine (15 mg) or placebo treatment.

8 Sibutramine, a centrally acting reuptake inhibitor of mo

9 n meal ("satiety") and the anti-obesity drug sibutramine, a serotonin and noradrenaline reuptake inhi

10 Sibutramine added to a behavior therapy program reduced

11 D) of 12.1+/-9.8 kg, whereas those receiving sibutramine alone lost 5.0+/-7.4 kg, those treated by li

12 Treatment with sibutramine also resulted in significantly greater reduc

13 nes may enhance response to multidimensional sibutramine and behavioral therapy for obesity.

14 Sibutramine and orlistat are the 2 most-studied drugs.

15 ontrast, two currently approved medications, sibutramine and orlistat, have been shown to be safe and

16 esults indicate that even though fluoxetine, sibutramine and sertraline do not deplete brain serotoni

17 Fluoxetine, sibutramine and sertraline treatment resulted in no depl

18 e second year: overall increases were 20.7% (sibutramine) and 11.7% (placebo, p<0.001).

19 ments or weight-loss medication (orlistat or sibutramine), chosen by the participants in consultation

20 fied and discriminated with respect to their sibutramine contents with perfect accuracy without any f

21 enotype variants (Delta weight loss in the 2 sibutramine doses vs placebo): alpha2A CC (Delta, approx

22 cific effect on brain function through which sibutramine exerts its clinical effect.

23 Weight-loss medications including sibutramine facilitate weight control in adults and coul

24 onth 12 (linear mixed-effects model) favored sibutramine for change from baseline in BMI (-2.9 kg/m2

25 7 to 12, adolescents initially treated with sibutramine gained 0.8 kg (10.5 kg) with continued use o

26 148 (42%) individuals in the sibutramine group and 58 (50%) in the placebo group drop

27 Seventy-six percent of patients in the sibutramine group and 62% of patients in the placebo gro

28 ic acid; these changes were sustained in the sibutramine group but not the placebo group.

29 The sibutramine group had greater improvements in triglyceri

30 lysis at month 6, participants in the BT and sibutramine group lost a mean (SD) of 7.8 kg (6.3 kg) an

31 greater reduction in weekly binge frequency (sibutramine group mean=2.7 [SD=1.7], placebo group mean=

32 acebo group mean=2.0 [SD=2.3]); weight loss (sibutramine group mean=4.3 kg [SD=4.8], placebo group me

33 cause of increases in blood pressure; in the sibutramine group, systolic blood pressure rose from bas

34 percentage of abstinence from binge eating (sibutramine group: 58.7%; placebo group: 42.8%); and red

35 receiving placebo, participants who received sibutramine had a significantly greater reduction in wee

36 Currently, two medications, orlistat and sibutramine, have been approved by the United States Foo

37 ons orlistat, phentermine hydrochloride, and sibutramine hydrochloride.

38 ebo-controlled trial to test the efficacy of sibutramine in binge eating disorder.

39 ive, rapid and reliable techniques to detect sibutramine in dietetic herbal foods, teas and dietary s

40 y explored, for the first time, detection of sibutramine in green tea, green coffee and mixed herbal

41 uble-blind trial to assess the usefulness of sibutramine in maintaining substantial weight loss over

42 om months 7 to 12, all participants received sibutramine in open-label treatment.

43 This trial demonstrated the efficacy of sibutramine in reducing binge eating, weight, and associ

44 tion was associated with both variables: the sibutramine-induced modulation of the hypothalamic respo

45 Sibutramine is a tertiary amine that has been shown to i

46 evidence suggests that the antiobesity agent sibutramine is effective in the treatment of binge eatin

47 Weight loss in response to sibutramine is highly variable.

48 , whereas those who switched from placebo to sibutramine lost an additional 1.3 kg (5.4 kg).

49 Sibutramine may be illicitly included in herbal slimming

50 erse drug effects included hypertension with sibutramine (mean increase, 0 mm Hg to 3.5 mm Hg) and ga

51 t loss were then randomly assigned 10 mg/day sibutramine (n=352) or placebo (n=115) for a further 18

52 months, participants received either BT and sibutramine or BT and placebo.

53 Site-specific behavior therapy plus 10 mg of sibutramine or placebo.

54 Sibutramine, orlistat, phentermine, probably diethylprop

55 ssigned 224 obese adults to receive 15 mg of sibutramine per day alone, delivered by a primary care p

56 Up-to-date meta-analyses of sibutramine, phentermine, and diethylpropion were identi

57 eling alone, delivered in 30 group sessions; sibutramine plus 30 group sessions of lifestyle-modifica

58 tion counseling (i.e., combined therapy); or sibutramine plus brief lifestyle-modification counseling

59 alone lost 6.7+/-7.9 kg, and those receiving sibutramine plus brief therapy lost 7.5+/-8.0 kg (P<0.00

60 A meta-analysis of sibutramine reported a mean difference in weight loss of

61 Fluoxetine, sibutramine, sertraline and dexfenfluramine all produced

62 of treatment with high doses of fluoxetine, sibutramine, sertraline, and dexfenfluramine for 4 days

63 Sibutramine, the latest anorectic to enter the market, i

64 For sibutramine, there is a rise in blood pressure and heart

65 The addition of sibutramine to a comprehensive behavioral program induce

66 Of the 204 sibutramine-treated individuals who completed the trial,

67 Gene pairs resulted in significantly greater sibutramine treatment effects on weight (both P < .002):

68 Sibutramine (U.S. Food and Drug Administration [FDA] app

69 The rate of tachycardia was greater with sibutramine vs. placebo (12.5% vs. 6.2%; difference, 6.3

70 Sibutramine was associated with significantly higher inc

71 Sibutramine was increased up to 20 mg/day if weight rega

72 eling remained even after participants given sibutramine were excluded from the analyses.

73 s for long-term treatment of obesity include sibutramine, which inhibits food intake, and orlistat, w

74 was attenuated by satiety (but unaffected by sibutramine), while the hypothalamic and amygdala respon